Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 134
- Pharmaceutical
European Cannabis Stocks Review: OCT Shares Fall As Co-Founder Divests, Cannabis Poland Secures Funding, & Akanda’s Legal Battle Continues
Oxford Cannabinoid Technologies THE pharmaceutical cannabis company has seen its shares drop around 25% this week, following weeks of the first significant growth in its share price for months.
- Policy & Regulation
European Round-Up: France’s CESE Calls For End To ‘Bitter Failure’ Of Cannabis Prohibition, Clever Leaves and Tilray Slash Portuguese Operations, & More From Czechia & Germany
FRANCE’s Economic, Social and Environmental Council (CESE) has released a ‘draft opinion’ calling for the legalisation of cannabis.
- Uncategorized
Europäisches Round-Up: Frankreichs CESE fordert ein Ende des “bitteren Scheiterns” der Cannabisprohibition, Clever Leaves und Tilray verkleinern portugiesische Betriebe und mehr aus Tschechien und Deutschland
Der französische Wirtschafts-, Sozial- und Umweltrat (CESE) hat einen “Entwurf einer Stellungnahme” veröffentlicht, in dem er die Legalisierung von Cannabis fordert.
- Opinion
Czechia Could Be A ‘Step Towards Convincing The Rest Of Europe To Create A Legal Cannabis Framework’
EARLIER this week, Czechia’s national anti-drug coordinator Jindřich Vobořil, described as the ‘locomotive’ driving rapid cannabis reform in the country, announced that draft legislation on cannabis legalisation will be ready as soon as March.
- Pharmaceutical
UK’s Medical Cannabis Industry Enjoys Strong Start To 2023
LAST week a flurry of positive announcements from across the UK’s medical cannabis industry were unveiled in signs the industry is wasting no time in shaking off the stagnation of 2022.
- Pharmaceutical
European Cannabis Stocks Review: Celadon Shares Jump After Regulatory Win, IM Cannabis Closes Private Placement, & More From SEED
IM Cannabis IM Cannabis saw its stock price jump by nearly 10% this week after it announced the receipt of US$500k in funding in a private placement led by two company insiders.
- Medical
Linnea SA Receives Swiss Narcotics License Allowing For The Production And Exportation Of High THC Active Pharmaceutical Ingredients
LINNEA SA (“Linnea,” or “the Company”), a leading pharmaceutical manufacturer with over 40 years of experience, has been granted a narcotics license by Swissmedic at the end of 2022.
- Companies
Kanabo Launches 2 New High-THC Vape Formulas As It Prepares To Compete On ‘Patient Care’ In 2023
KANABO announced the launch of two new additions to its range of VapePod formulas this week, in what is expected to be the first in a flurry of announcements due in the coming months.
- Opinion
To Remove The Stigma Around Hemp ‘You Need A Better Understanding And Knowledge Of What You’re Stigmatising, That’s Exactly What’s Happening Now’
FOLLOWING the publication of a special report on industrial hemp, The United Nations Conference on Trade and Development (UNCTAD) is set to host a workshop tomorrow (Wednesday January 18, 2023).
- Markets & Stocks
European Cannabis Stocks Review: Khiron Spikes On Colombian Insurance Deal, Apollon Divests Patents, & More From Seach Medical
Khiron Life Sciences INTERNATIONAL medical cannabis company Khiron has seen its share price skyrocket over 60% following a crucial resolution that was passed by the Colombian Ministry of Health.
- Medical
Italian Army Pledges To More Than Double Medical Cannabis Production This Year, But Supply Issues Far From Over
THE Italian army, which continues to hold a monopoly over medical cannabis production, has announced plans to dramatically ramp up production this year.
- Medical
Spain Misses Ambitious Medical Cannabis Roll Out Targets As Government Remains Tight-Lipped On Progress
SPAIN’s ambitious plans to see the regulation and distribution of medical cannabis rolled out across the country by the end of 2022 appear to have been delayed.











